In
this study we will therefore directly compare the effects of VD, Atorvastatin
(increases 25-OHD), and Fluvastatin (which does not increase 25-OHD), on CVD
risk factors in women with PCOS.
These
investigations may clarify whether the clinical benefits of statins are
mediated through the protective effect of increased VD levels, rather than or
as well as lipid lowering. This may refute or justify VD supplementation alone,
the prescription of a specific type of statin, or even replacement of statin
expensive treatment by VD, a safe and affordable drug, in women with PCOS.
Adult
women with PCOS attending the Women’s Health Center (WHC) and the outpatient
Obstetrics and Gynecology clinics (OPD) at the American University of Beirut
Medical Center (AUBMC) in Beirut, Lebanon.
purposeful sampling
- Women between 18-35 years of age meeting the criteria for the diagnosis of PCOS according to the Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group.
-
Not planning to
conceive and using non – hormonal method for contraception (barrier method).
-
No concurrent
illness and not on any prescription or over the counter medication or vitamin
that was likely to affect insulin sensitivity, lipids, vitamin D, including
hormonal contraception for the preceding 6 months.
-
No prior statin
therapy in the last 6 months.
-
Thyroid disease
-
Hyperprolactinemia
(>30 ug/l)
-
Cushing’s
disease
-
Androgen secreting
tumors
-
Non classical
21-hydroxylase deficiency
-
Chronic medical
illness (liver, kidney disease)
-
Previously known
to have kidney stones
-
Diagnosis of
cancer
-
Taking a drug
that affects inflammatory markers: Aspirin, Non- Steroidal Inflammatory Drugs,
etc….
-
Taking lipid or
glucose lowering drugs: xenical, fibers, acarbose, metformin within the last 6
months, etc...
-
Taking vitamin D
supplements
-
Pregnancy